Spectrum Pharmaceuticals, Inc. - Product Pipeline Review - 2016

Published: Apr, 2016 | Pages: 81 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Spectrum Pharmaceuticals, Inc. - Product Pipeline Review - 2016

Summary

Global Markets Direct's, 'Spectrum Pharmaceuticals, Inc. - Product Pipeline Review - 2016', provides an overview of the Spectrum Pharmaceuticals, Inc.'s pharmaceutical research and development focus. 

The report provides comprehensive information on the therapeutics under development by Spectrum Pharmaceuticals, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of Spectrum Pharmaceuticals, Inc.
- The report provides overview of Spectrum Pharmaceuticals, Inc. including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report assesses Spectrum Pharmaceuticals, Inc.'s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report features Spectrum Pharmaceuticals, Inc.'s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons To Buy

- Evaluate Spectrum Pharmaceuticals, Inc.'s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Spectrum Pharmaceuticals, Inc.
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Spectrum Pharmaceuticals, Inc.'s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope

 Table of Contents

Table of Content 2
List of Tables 5
List of Figures 5
Spectrum Pharmaceuticals, Inc. Snapshot 6
Spectrum Pharmaceuticals, Inc. Overview 6
Key Information 6
Key Facts 6
Spectrum Pharmaceuticals, Inc. - Research and Development Overview 7
Key Therapeutic Areas 7
Spectrum Pharmaceuticals, Inc. - Pipeline Review 10
Pipeline Products by Stage of Development 10
Pipeline Products - Monotherapy 11
Pipeline Products - Partnered Products 12
Partnered Products/Combination Treatment Modalities 13
Spectrum Pharmaceuticals, Inc. - Pipeline Products Glance 14
Spectrum Pharmaceuticals, Inc. - Late Stage Pipeline Products 14
Pre-Registration Products/Combination Treatment Modalities 14
Phase III Products/Combination Treatment Modalities 15
Spectrum Pharmaceuticals, Inc. - Clinical Stage Pipeline Products 16
Phase II Products/Combination Treatment Modalities 16
Phase I Products/Combination Treatment Modalities 17
Spectrum Pharmaceuticals, Inc. - Early Stage Pipeline Products 18
Preclinical Products/Combination Treatment Modalities 18
Spectrum Pharmaceuticals, Inc. - Unknown Stage Pipeline Products 19
Unknown Products/Combination Treatment Modalities 19
Spectrum Pharmaceuticals, Inc. - Drug Profiles 20
apaziquone 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
vincristine sulfate 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
eflapegrastim 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
belinostat 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
menadione sodium bisulfite 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
ozarelix 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
poziotinib 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
pralatrexate 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
SPI-014 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
SPI-1620 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Alocrest 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
MTRN-2696 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
SPI-205 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
topotecan hydrochloride 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
melphalan 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Yttritum 90 ibritumomab tiuxetan 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
Spectrum Pharmaceuticals, Inc. - Pipeline Analysis 49
Spectrum Pharmaceuticals, Inc. - Pipeline Products by Target 49
Spectrum Pharmaceuticals, Inc. - Pipeline Products by Route of Administration 51
Spectrum Pharmaceuticals, Inc. - Pipeline Products by Molecule Type 52
Spectrum Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action 53
Spectrum Pharmaceuticals, Inc. - Recent Pipeline Updates 55
Spectrum Pharmaceuticals, Inc. - Dormant Projects 76
Spectrum Pharmaceuticals, Inc. - Discontinued Pipeline Products 77
Discontinued Pipeline Product Profiles 77
efaproxiral 77
ortataxel 77
RH-1 77
Spectrum Pharmaceuticals, Inc. - Company Statement 78
Spectrum Pharmaceuticals, Inc. - Locations And Subsidiaries 79
Head Office 79
Other Locations & Subsidiaries 79
Appendix 80
Methodology 80
Coverage 80
Secondary Research 80
Primary Research 80
Expert Panel Validation 80
Contact Us 80
Disclaimer 81

List of Tables

Spectrum Pharmaceuticals, Inc., Key Information 6
Spectrum Pharmaceuticals, Inc., Key Facts 6
Spectrum Pharmaceuticals, Inc. - Pipeline by Indication, 2016 8
Spectrum Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2016 10
Spectrum Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2016 11
Spectrum Pharmaceuticals, Inc. - Partnered Products in Pipeline, 2016 12
Spectrum Pharmaceuticals, Inc. - Partnered Products/ Combination Treatment Modalities, 2016 13
Spectrum Pharmaceuticals, Inc. - Pre-Registration, 2016 14
Spectrum Pharmaceuticals, Inc. - Phase III, 2016 15
Spectrum Pharmaceuticals, Inc. - Phase II, 2016 16
Spectrum Pharmaceuticals, Inc. - Phase I, 2016 17
Spectrum Pharmaceuticals, Inc. - Preclinical, 2016 18
Spectrum Pharmaceuticals, Inc. - Unknown, 2016 19
Spectrum Pharmaceuticals, Inc. - Pipeline by Target, 2016 49
Spectrum Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2016 51
Spectrum Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2016 52
Spectrum Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2016 54
Spectrum Pharmaceuticals, Inc. - Recent Pipeline Updates, 2016 55
Spectrum Pharmaceuticals, Inc. - Dormant Developmental Projects,2016 76
Spectrum Pharmaceuticals, Inc. - Discontinued Pipeline Products, 2016 77
Spectrum Pharmaceuticals, Inc., Other Locations 79
Spectrum Pharmaceuticals, Inc., Subsidiaries 79